Sequentia supports R&D to face COVID-19

Sequentia Biotech is supporting R&D in COVID-19 by making GAIA, its microbiome analysis software,  able to detect and analyze SARS-CoV-2 NGS data with high precision and sensitivity, in a fast and easy way.
We are committed with researchers who are constantly trying to get a better and deeper understanding of the virus and new diagnosis and therapeutics methods, that’s why we updated GAIA and delivered a powerful tool that the scientific community can rely on.
  • Detects SARS-CoV-2 with high precision and sensibility.* 
  • Performs SARS-CoV-2 strain identification, even in complex viral matrices. 
  • Updated and curated SARS-CoV-2 databases. 
  • Works with Amplicon and Shotgun sequencing. 
  • Works with any biological sample.
  • Works with data from any NGS platform (Illumina, Oxford Nanopore, PacBio, IonTorrent).
  • Optimized for Oxford Nanopore sequencing.** 

* Illumina: 100% precision; 99,2% sensitivity. Oxford Nanopore: 99,6% precision; 87,9% sensitivity.

** Improves the discrimination of chimeric reads.


We're not around right now. But you can send us an email and we'll get back to you, asap.


Log in with your credentials

Forgot your details?